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Abstract Pyrrolo[3,4-c]pyrazole-4,6(1H,5H)-dione, pyrano[2,3-c]pyrazole-5-carbonitrile,
pyrano[2,3-d]4-imidazolines, pyrido[2,1-b]benzimidazole, pyrido[2,1-b][1,3]benzoxazole, pyrido[2,1-Pyrano[2,3-c]pyrazole;
Pyrido[2,1-
b]benzimidazole;
Pyrido[2,1-
b][1,3]benzoxazole;
b][1,3]benzothiazole and pyrido[2,1-b]quinazoline were synthesised from antipyrine derivatives with
appropriate reagents such as maleimides, malononitrile, ethyl cyanoacetate, benzimidazole-2-acetonitrile,
benzothiazole-2-acetonitrile, benzoxazol-2-acetonitrile, benzoylacetonitrile and other reagents. The newly
synthesised compounds were established by elemental analysis, spectral data, and alternative synthetic
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b][1,3]benzothiazole;
Pyrido[2,1-b]quinazoline
routes whenever possible.
Introduction
Antipyrine derivatives have attracted the attention of several
research groups due their potential activities [1–5]. In this, a
broad spectrum of bioactive antipyrine derivatives have been inves-
tigated and diversities of bioactivities such as analgesic [6,7]
anti-inflammatory, [8] antimicrobial, [9–11] and anticancer activity
[12] have been reported. In continuation of our research [13–18], we
report herein the synthesis of some new heterocycles incorporating
the antipyrine moiety starting from 4-formylantipyrine.
Experimental
All melting points were determined on an electrothermal appara-
tus and are reported here uncorrected. IR spectra were recorded
(KBr discs) on a Shimadzu FT-IR 8201 PC spectrophotometer. 1H∗ Corresponding author. Tel.: +202 37489611; fax: +202 35727556.
E-mail address: Abdelhamid45@gmail.com (A.O. Abdelhamid).
2090-1232 © 2010 Cairo University. Production and hosting by Elsevier. All
rights reserved. Peer review under responsibility of Cairo University.
Production and hosting by Elsevier
h
4
T
4
(
T
2
(
3
doi:10.1016/j.jare.2010.03.005© 2010 Cairo University. All rights reserved.
MR spectra were recorded in CDCl3 and (CD3)2SO solutions on
Varian Gemini 300 MHz spectrometer and chemical shifts were
xpressed in δ units using TMS as an internal reference. Elemental
nalyses were carried out at the Microanalytical Center of the Cairo
niversity.
-Aryl-tetrahydro-3-(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-
H-pyrazol-4-yl)-1-phenylpyrrolo[3,4-c]pyrazole-4,6(5H,6aH)-
ione 3a–c and 5-aryl-1,6a-dihydro-3-(2,3-dihydro-1,5-dimethyl-
-oxo-2-phenyl-1H-pyrazol-4-yl)-1-phenylpyrrolo[3,4-c]pyrazole-
,6(3aH,5H)-dione 4a–c
quimolar amounts of the appropriate N-arylmaleimides
nd 1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-
arbaldehyde phenylhydrazone (5 mmoles) in anisole (20 mL) was
oiled under reflux for 3 h. The reaction mixture was filtered while
ot to give 3a–c, and then the filtrate evaporated to its half to give
a–c, respectively.
etrahydro-3-(2,3-dihydro-1-methyl-3-oxo-2-phenyl-1H-pyrazol-
-yl)-1,5-diphenylpyrrolo[3,4-c]pyrazole-4,6(5H,6aH)-dione
3a)his compound was obtained as yellow crystals (AcOH), mp
35–36 ◦C, yield (37%); IR (cm−1): 3320 (NH), 1705, 1691, 1682
CO’s), and 1595 (C C). 1H NMR (CD3)2SO δ= 2.42 (s, 3H, CH3),
.25 (s, 3H, CH3), 3.49 (t, 1H, J = 7.5 Hz, pyrazoline H-4), 4.64
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1H-benzimidazol-2-ylacetonitrile, 1,3-benzoxazol-2-ylacetonitrile,38
d, 1H, J = 7 Hz, pyrazoline H-5), 5.86 (t, 1H, pyrazoline H-3),
.67–7.75 (m, 15H, ArH’s), 10.05 (s, br., 1H, NH). Anal. Calcd.
or C28H25N5O3 (479.54): C, 70.13; H, 5.25; N, 14.60. Found: C,
0.00, H; 5.10; N, 14.70.
etrahydro-3-(2,3-dihydro-1-methyl-3-oxo-2-phenyl-1H-pyrazol-
-yl)-1-phenyl-5-p-tolylpyrrolo[3,4-c]pyrazole-4,6(5H,6aH)-
ione (3b)
his compound was obtained as yellow crystals (AcOH), mp
40–242 ◦C, yield (42%); IR (cm−1): 3330 (NH), 1705, 1691, 1682
CO’s), and 1600 (C C). 1H NMR (CD3)2SO: δ= 2.28 (s, 3H, CH3),
.42 (s, 3H, CH3), 3.25 (s, 3H, CH3), 3.49 (t, 1H, J = 7.5 Hz, pyra-
oline H-4), 4.64 (d, 1H, J = 7 Hz, pyrazoline H-5), 5.86 (t, 1H,
yrazoline H-3), 6.67–7.75 (m, 14H, ArH’s), 10.05 (s, br., 1H, NH).
nal. Calcd. for C29H27N5O3 (493.56): C, 70.57; H, 5.50; N, 14.18.
ound: C, 70.32, H; 5.64; N, 14.00.
-(4-Chlorophenyl)-tetrahydro-3-(2,3-dihydro-1-methyl-3-oxo-2-
henyl-1H-pyrazol-4-yl)-1-phenylpyrrolo[3,4-c]pyrazole-
,6(5H,6aH)-dione (3c)
his compound was obtained as yellow crystals (AcOH), mp
42–44 ◦C, yield (37%); IR (cm−1): 3330 (NH), 1705, 1691, 1682
CO’s), and 1600 (C C). 1H NMR (CD3)2SO: δ= 2.42 (s, 3H, CH3),
.25 (s, 3H, CH3), 3.49 (t, 1H, J = 7.5 Hz, pyrazoline H-4), 4.64
d, 1H, J = 7 Hz, pyrazoline H-5), 5.86 (t, 1H, pyrazoline H-3),
.67–7.75 (m, 14H, ArH’s), 10.05 (s, br., 1H, NH). Anal. Calcd.
or C28H24ClN5O3 (513.98): C, 65.43; H, 4.70; N, 13.62. Found: C,
5.34, H; 4.66; N, 13.51.
-Aryl-1,6a-dihydro-3-(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-
H-pyrazol-4-yl)-1-phenylpyrrolo[3,4-c]pyrazole-4,6(3aH,5H)-
ione 4a–c
mixture of the appropriate N-arylmalemide (5 mmoles),
,5-dimethyl-3-oxo-N,2-diphenyl-2,3-dihydro-1H-pyrazole-4-
arbohydrazonoyl bromide (6) (1.9 g, 5 mmoles) and triethylamine
0.75 mL, 5 mmoles) in dry toluene (20 mL) was refluxed for
h. The reaction was filtered, and the solvent evaporated till
ryness under reduced pressure and triturated with petroleum ether
40–60 ◦C). The resulting was collected and recrystallised from
cetic acid to give 4a–c.
,6a-Dihydro-3-(2,3-dihydro-1-methyl-3-oxo-2-phenyl-1H-
yrazol-4-yl)-1,5-diphenylpyrrolo[3,4-c]pyrazole-4,6(3aH,5H)-
ione (4a)
his compound was obtained as yellow crystals (AcOH), mp
70–73 ◦C, yield (54%); IR (cm−1): 1705, 1691, 1682 (CO’s), and
600 (C C). 1H NMR (CD3)2SO: δ= 2.61 (s, 3H, CH3), 3.24 (s,
H, CH3), 4.88 (d, 1H, J = 9 Hz, pyrazoline H-4), 5.85 (d, 1H,
= 9 Hz, pyrazoline H-5), 6.98–7.58 (m, 15H, ArH’s). Anal. Calcd.
or C28H23N5O3 (4.77.52): C, 70.42; H, 4.85; N, 14.66. Found: C,
0.31, H; 4.62; N, 14.55.
,6a-Dihydro-3-(2,3-dihydro-1-methyl-3-oxo-2-phenyl-1H-
yrazol-4-yl)-1-phenyl-5-p-tolylpyrrolo[3,4-c]pyrazole-
,6(3aH,5H)-dione (4b)
his compound was obtained as yellow crystals (AcOH), mp
53–55 ◦C, yield (55%); IR (cm−1): 1705, 1691, 1682 (CO’s), and
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600 (C C). 1H NMR (CD3)2SO: δ= 2.32 (s, 3H, CH3), 2.61 (s,
H, CH3), 3.24 (s, 3H, CH3), 4.88 (d, 1H, J = 9 Hz, pyrazoline H-4),
.85 (d, 1H, J = 9 Hz, pyrazoline H-5), 6.98–7.58 (m, 14H, ArH’s).
nal. Calcd. for C29H24N5O3 (491.55): C, 70.86; H, 5.12; N, 14.24.
ound: C, 70.68, H; 5.04; N, 14.10.
-(4-Chlorophenyl)-1,6a-dihydro-3-(2,3-dihydro-1-methyl-3-oxo-
-phenyl-1H-pyrazol-4-yl)-1-phenylpyrrolo[3,4-c]pyrazole-
,6(3aH,5H)-dione (4c)
his compound was obtained as yellow crystals (AcOH), mp
58–59 ◦C, yield (45%); IR (cm−1): 1705, 1691, 1682 (CO’s), and
600 (C C). 1H NMR (CD3)2SO: δ= 2.61 (s, 3H, CH3), 3.24 (s,
H, CH3), 4.88 (d, 1H, J = 9 Hz, pyrazoline H-4), 5.85 (d, 1H,
= 9 Hz, pyrazoline H-5), 6.98–7.58 (m, 14H, ArH’s). Anal. Calcd.
or C28H22ClN5O3 (511.97): C, 65.69; H, 4.33; N, 13.67. Found: C,
5.82, H; 4.21; N, 13.87.
-(4-Chlorophenyl)-3-(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-
H-pyrazol-4-yl)-1-phenyl-pyrrolo[3,4-c]pyrazole-4,6(1H,5H)-
ione (5c)
mixture of 4c (0.5 g, 5 mmoles) and p-chloroanil (0.25 g,
mmoles) in xylene (20 mL) was heated under reflux for 48 h.
he reaction mixture was washed with sodium hydroxide (0.1N,
5 mL × 3), and then dried over magnesium sulphate anhydrous.
ylene was evaporated under vacuum, and the resulting solid was
ollected and recrystallised from acetic acid to give 5c. This com-
ound was obtained as yellow crystals (AcOH), mp 258–59 ◦C, yield
78%); IR (cm−1): 1705, 1691, 1682 (CO’s), and 1600 (C C). 1H
MR (CD3)2SO: δ= 2.42 (s, 3H, CH3), 3.25 (s, 3H, CH3), 7.18–7.78
m, 14H, ArH’s). Anal. Calcd. for C28H22ClN5O3 (509.97): C,
5.94; H, 3.95; N, 13.73. Found: C, 65.88, H; 4.10; N, 13.56.
,5-Dimethyl-3-oxo-N,2-diphenyl-2,3-dihydro-1H-pyrazole-4-
arbohydrazonoyl bromide (6)
mixture of 1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-
yrazole-4-carbaldehyde phenylhydrazone (1.5 g, 5 mmoles) and
-bromosuccinimide (0.43 g, 5 mmoles) in toluene (20 mL) was
eated under reflux for 2 h. The reaction mixture was evaporated
nder vacuum to its half, and then triturated with petroleum ether
40–60 ◦C). The resulting solid was collected and recrystallised
rom acetic to give 6. This compound was obtained as yellow
rystals (AcOH), mp 240–43 ◦C, yield (77%); IR (cm−1): 3350
NH), 1691 (CO), and 1600 (C C). 1H NMR (CDCl3): δ= 2.22 (s,
H, CH3), 3.25 (s, 3H, CH3), 6.71–7.84 (m, 10H, ArH’s), 8.92 (s,
r., 1H, NH). Anal. Calcd. for C18H17BrN4O (385.27): C, 56.12;
, 4.45; N, 14.54. Found: C, 56.10, H; 4.64; N, 14.35.
ynthesis of 7–13
eneral procedure: A mixture of 2,5-dihydro-2,3-dimethyl-5-
xo-1-phenyl-1H-pyrazole-4-carbaldehyde (1) (1.03 g, 5 mmoles)
nd the appropriate of malononitrile, ethyl cyanoacetate,,3-benothiazole-2-ylacetonitrile, (4-oxo-3,4-dihydroquinazolin-2-
l)acetonitrile or 3-oxo-3-phenylpropanenitrile (5 mmoles) in
thanol (20 mL) was heated under reflux for 30 min. The resulting
as collected and recrystallised from ethanol to give compounds
–13, respectively.
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2-((2,5-Dihydro-2,3-dimethyl-5-oxo-1-phenyl-1H-pyrazol-4-
yl)methylene)-malononitrile (7)
This compound was obtained as yellow crystals (EtOH), mp
231–33 ◦C, yield (92%); IR (cm−1): 2191, 2178 (CN), 1705, 1691
(CO), and 1595 (C C). 1H NMR (CDCl3): δ= 2.32 (s, 3H, CH3),
3.15 (s, 3H, CH3), 6.93 (s, 1H, CH C(CN)2), 7.13–7.74 (m, 5H,
ArH’s). Anal. Calcd. for C15H12N4O (264.29): C, 68.17; H, 4.58;
N, 21.20. Found: C, 68.00, H; 4.75; N, 21.00.
Ethyl 2-cyano-3-(2,5-dihydro-2,3-dimethyl-5-oxo-1-phenyl-1H-
pyrazol-4-yl)acrylate (8)
This compound was obtained as yellow crystals (EtOH), mp 145 ◦C,
yield (82%); ir (cm−1): 2191 (CN), 1715, 1691 (CO’s), and 1595
(C C). 1H NMR (CDCl3): δ= 1.32 (t, 3H, CH2CH3), 2.32 (s, 3H,
CH3), 3.15 (s, 3H, CH3), 4.22 (q, 2H, CH2CH3), 7.13–7.74 (m,
5H, ArH’s) and CH CN(CO2C2H5). Anal. Calcd. for C17H17N3O3
(311.34): C, 65.58; H, 5.50; N, 13.50. Found: C, 65.42, H; 5.45; N,
13.40.
2-(1H-benzimidazol-2-yl)-3-(1,5-dimethyl-3-oxo-2-phenyl-2,3-
dihydro-1H-pyrazol-4-yl)acrylonitrile (9)
This compound was obtained as yellow crystals (EtOH), mp
295–97 ◦C, yield (88%); IR (cm−1): 3230 (NH), 2191 (CN), 1691
(CO), and 1595 (C C). 1H NMR (CDCl3): δ= 2.11 (s, 3H, CH3),
3.16 (s, 3H, CH3), 7.12–8.21 (m, 10H, ArH’s and CH ), 11.42 (s,
1H, NH). Anal. Calcd. for C21H17N5O (355.40): C, 70.97; H, 4.82;
N, 19.71. Found: C, 71.12, H; 4.72; N, 19.85.
2-(1,3-Benzoxazol-2-yl)-3-(1,5-dimethyl-3-oxo-2-phenyl-2,3-
dihydro-1H-pyrazol-4-yl)acrylonitrile (10)
This compound was obtained as yellow crystals (EtOH), mp
228–29 ◦C, yield (80%); IR (cm−1): 2195 (CN), 1691 (CO), 1620
(C N), and 1600 (C C). 1H NMR (CDCl3): δ= 2.11 (s, 3H, CH3),
3.16 (s, 3H, CH3), 7.12–8.11 (m, 10H, ArH’s and CH ). Anal.
Calcd. for C21H16N4O2 (356.39): C, 70.78; H, 4.53; N, 15.72. Found:
C, 70.67; H, 4.35; N, 15.61.
2-(1,3-Benzothiazol-2-yl)-3-(1,5-dimethyl-3-oxo-2-phenyl-2,3-
dihydro-1H-pyrazol-4-yl)-acrylonitrile (11)
This compound was obtained as yellow crystals (EtOH), mp
230–32 ◦C, yield (82%); IR (cm−1): 2190 (CN), 1686 (CO), 1620
(C N), and 1600 (C C). 1H NMR (CDCl3): δ= 2.11 (s, 3H, CH3),
3.16 (s, 3H, CH3), 7.12–8.32 (m, 10H, ArH’s and CH ). Anal.
Calcd. for C21H16N4OS (372.45): C, 67.72; H, 4.33; N, 15.04; S,
8.61. Found: C, 67.52; H, 4.12; N, 15.04; S, 8.82.
3-(1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)-2-
(4-oxo-3,4-dihydroquinazolin-2-yl)acrylonitrile (12)This compound was obtained as yellow crystals (EtOH), mp
240–43 ◦C, yield (76%); IR (cm−1): 3350 (NH), 2195 (CN), 1691
(CO), 1620 (C N), and 1600 (C C). 1H NMR (CD3)2SO: δ= 2.11
(s, 3H, CH3), 3.16 (s, 3H, CH3), 7.15–8.12 (m, 10H, ArH’s and
CH ), 11.35 (s, 1H, NH). Anal. Calcd. for C22H17N5O2 (383.41):
C, 68.92; H, 4.47; N, 18.27. Found: C, 69.10; H, 4.47; N, 18.00.
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-Benzoyl-3-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-
yrazol-4-yl)acrylonitrile (13)
his compound was obtained as yellow crystals (EtOH), mp
53–55 ◦C, yield (84%); IR (cm−1): 2195 (CN), 1691, 1662 (CO’s),
620 (C N), and 1600 (C C). 1H NMR (CDCl3): δ= 2.11 (s, 3H,
H3), 3.16 (s, 3H, CH3), 7.23–7.92 (m, 11H, ArH’s and CH ).
nal. Calcd. for C21H17N3O2 (343.39): C, 73.32; H, 4.99; N, 12.24.
ound: C, 73.32; H, 5.12; N, 12.40.
ynthesis 14 and 15
ethod A: Equimolar amounts of 7, the appropriate of
-methyl-1H-pyrazol-5(4H)-one (0.49 g, 5 mmoles) or 3-methyl-
-phenyl-1H-pyrazol-5(4H)-one (0.87 g, 5 mmoles) and catalytic
mounts of piperidine in ethanol (20 mL) were heated under reflux
or 2 h. The resulting solid was collected and recrystallised from
thanol to give 14 and 15, respectively.
Method B: A mixture of 1 (1.03 g, 5 mmoles), malononitrile
0.33 g, 5 mmoles), the appropriate of 3-methyl-1H-pyrazol-5(4H)-
ne (049 g, 5 mmoles) or 3-methyl-1-phenyl-1H-pyrazol-5(4H)-one
0.87 g, 5 mmoles) and catalytic amounts of piperidine in ethanol
20 mL) were stirred at room temperature for 4 h. The resulting
olid was collected and recrystallised from ethanol to give iden-
ical product in all aspects (mp, mixed mp and spectra) with 14 and
5, respectively.
-Amino-1,4-dihydro-4-(2,3-dihydro-1,5-dimethyl-3-oxo-2-
henyl-1H-pyrazol-4-yl)-3-methylpyrano[2,3-c]pyrazole-5-
arbonitrile (14)
his compound was obtained as yellow crystals (EtOH), mp
08–210 ◦C, yield (86%); IR (cm−1): 3350, 3280, 3190 (NH, NH2),
195 (CN), 1691 (CO), 1620 (C N), and 1600 (C C). 1H NMR
CDCl3): δ= 1.98 (s, 3H, CH3), 2.11 (s, 3H, CH3), 3.16 (s, 3H,
H3), 4.80 (s, 1H, pyran H-4), 6.22 (s, 2H, NH2), 7.13–7.92 (m, 5H,
rH’s), 8.11 (s, 1H, NH). Anal. Calcd. for C19H18N6O2 (362.39):
, 62.97; H, 5.01; N, 23.19. Found: C, 62.88; H, 5.00; N, 23.12.
-Amino-1,4-dihydro-4-(2,3-dihydro-1,5-dimethyl-3-oxo-2-
henyl-1H-pyrazol-4-yl)-3-methyl-1-phenyl-pyrano[2,3-
]pyrazole-5-carbonitrile (15)
his compound was obtained as yellow crystals (EtOH), mp
03–305 ◦C, yield (78%); IR (cm−1): 3280, 3190 (NH2), 2195 (CN),
691 (CO), 1620 (C N), and 1600 (C C). 1H NMR (CDCl3):
= 1.98 (s, 3H, CH3), 2.11 (s, 3H, CH3), 3.16 (s, 3H, CH3), 4.80
s, 1H, pyran H-4), 6.22 (s, 2H, NH2), 7.13–7.92 (m, 10H, ArH’s).
nal. Calcd. for C25H22N6O2 (438.48): C, 68.48; H, 5.06; N, 19.17.
ound: C, 68.42; H, 5.00; N, 19.25.
-[(2,3-Dimethyl-5-oxo-1-phenyl(3-pyrazolin-4-yl))methylene]-5-
ethyl-2-phenyl-1-pyrazolin-4-one (16)
quimolar amounts of 1, 3-methyl-1-phenyl-1H-pyrazol-5(4H)-one
0.87 g, 5 mmoles) and catalytic amounts of piperidine in ethanol
20 mL) were heated under reflux for 2 h. The resulting solid was
ollected and recrystallised from ethanol to give 16. This compound
as obtained as yellow crystals (EtOH), mp 180–2 ◦C, yield (72%);
R (cm−1): 1691 (CO), 1620 (C N), and 1600 (C C). 1H NMR
CDCl3): δ= 1.98 (s, 3H, CH3), 2.11 (s, 3H, CH3), 3.16 (s, 3H, CH3),
.13–7.92 (m, 10H, ArH’s), 8.54 (s, 1H, CH C, vinyl). Calcd. for
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22H20N4O2 (372.43): C, 70.95; H, 5.41; N, 15.04. Found: C, 71.10;
, 5.32; N, 15.00.
ynthesis of 17–27 and 29
eneral procedure: Equimolar amounts of the appropriate 7–13,
he appropriate of 2-thioxoimidazolidin-4-one, 1-phenyl-2-
hioxoimidazolidin-4-one, 3-phenyl-2-thioxoimidazolidin-4-one,
,3-diphenyl-2-thioxoimidazolidin-4-one or the appropriate of
-(1H-benzo[d]imidazol-2-yl)acetonitrile,2-(benzo[d]oxazol-2-
l)acetonitrile,2-(benzo[d]thiazol-2-yl)acetonitrile (5 mmoles)
nd catalytic amounts of piperidine in ethanol (20 mL) were
eated under reflux for 2 h. The resulting solid was collected and
ecrystallised from ethanol to give 17–29, respectively.
-Amino-1,2,3,7-tetrahydro-7-(2,3-dihydro-1,5-dimethyl-3-oxo-2-
henyl-1H-pyrazol-4-yl)-2-thioxopyrano[3,2-d]imidazole-6-
arbonitrile (17)
his compound was obtained as yellow crystals (AcOH), mp
60–63 ◦C, yield (80%); IR (cm−1): 3347 (NH), 3280, 3210 (NH,
H2), 2221 (CN), 1685 (CO), 1620 (C N), and 1600 (C C). 1H
MR (CDCl3): δ= 2.11 (s, 3H, CH3), 3.16 (s, 3H, CH3), 5.32 (s,
H, pyran H-4), 6.22 (s, br., 2H, NH2), 7.13–7.72 (m, 5H, ArH’s),
.89 (s, br., 2H, 2NH). Calcd. for C18H16N6O2S (380.43): C, 56.83;
, 4.24; N, 22.09; S, 8.43. Found: C, 56.90; H, 4.00; N, 21.85; S,
.34.
-Amino-1,2,3,7-tetrahydro-7-(2,3-dihydro-1,5-dimethyl-3-oxo-2-
henyl-1H-pyrazol-4-yl)-1-phenyl-2-thioxopyrano[3,2-d]
midazole-6-carbonitrile (18)
his compound was obtained as yellow crystals (AcOH), mp
30–31 ◦C, yield (75%); IR (cm−1): 3347, 3280, 3210 (NH, NH2),
221 (CN), 1685 (CO), 1620 (C N), and 1600 (C C). 1H NMR
CDCl3): δ= 2.11 (s, 3H, CH3), 3.16 (s, 3H, CH3), 5.43 (s, 1H,
yran H-4), 6.32 (s, br., 2H, NH2), 7.13–7.72 (m, 10H, ArH’s), 8.49
s, br., 1H, NH). Calcd. for C24H20N6O2S (456.53): C, 63.14; H,
.42; N, 18.41; S, 7.02. Found: C, 63.21; H, 4.52; N, 18.60; S, 7.00.
-Amino-1,2,3,7-tetrahydro-7-(2,3-dihydro-1,5-dimethyl-3-oxo-2-
henyl-1H-pyrazol-4-yl)-3-phenyl-2-thioxopyrano[3,2-
]imidazole-6-carbonitrile (19)
his compound was obtained as yellow crystals (AcOH), mp
46–48 ◦C, yield (75%); IR (cm−1): 3347, 3280, 3210 (NH, NH2),
221 (CN), 1685 (CO), 1620 (C N), and 1600 (C C). 1H NMR
CDCl3): δ= 2.11 (s, 3H, CH3), 3.16 (s, 3H, CH3), 5.43 (s, 1H,
yran H-4), 6.32 (s, br., 2H, NH2), 6.95–7.75 (m, 10H, ArH’s), 9.42
s, br., 1H, NH). Calcd. for C24H20N6O2S (456.53): C, 63.14; H,
.42; N, 18.41; S, 7.02. Found: C, 63.00; H, 4.32; N, 18.37; S, 7.00.
-Amino-1,2,3,7-tetrahydro-7-(2,3-dihydro-1,5-dimethyl-3-oxo-2-
henyl-1H-pyrazol-4-yl)-1,3-diphenyl-2-thioxopyrano[3,2-
]imidazole-6-carbonitrile (20)his compound was obtained as yellow crystals (AcOH), mp 135 ◦C,
ield (72%); IR (cm−1): 3280, 3210 (NH2), 2221 (CN), 1685 (CO),
620 (C N), and 1600 (C C). 1H NMR (CD3)2SO: δ= 2.11 (s,
H, CH3), 3.16 (s, 3H, CH3), 5.66 (s, 1H, pyran H-4), 6.32 (s, br.,
H, NH2), 6.85–7.75 (m, 15H, ArH’s). Calcd. for C30H24N6O2S
3
2
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532.63): C, 67.65; H, 4.52; N, 15.78; S, 6.02. Found: C, 67.55; H,
.35; N, 15.82; S, 6.00.
-Amino-3-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-
yrazol-4-yl)pyrido[1,2-a]benzimidazole-2,4-dicarbonitrile (21)
his compound was obtained as yellow crystals (DMF), mp
80–82 ◦C, yield (72%); IR (cm−1): 3280, 3210 (NH2), 2221,
195 (CN), 1682 (CO), 1620 (C N), and 1600 (C C). 1H NMR
CD3)2SO: δ= 2.22 (s, 3H, CH3), 3.12 (s, 3H, CH3), 7.12–8.24 (m,
1H, ArH’s and NH2). Calcd. for C24H17N7O (419.45): C, 68.73;
, 4.09; N, 23.38. Found: C, 68.85; H, 4.00; N, 23.12.
-Amino-3-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-
yrazol-4-yl)-3H-pyrido[2,1-b][1,3]benzoxazole-2,4-
icarbonitrile (22)
his compound was obtained as yellow crystals (EtOH), mp
93–95 ◦C, yield (81%); IR (cm−1): 3280, 3210 (NH2), 2216,
195 (CN), 1680 (CO), 1620 (C N), and 1595 (C C). 1H NMR
CD3)2SO: δ= 2.11 (s, 3H, CH3), 3.16 (s, 3H, CH3), 5.51 (s, 1H,
yran H-4), 6.32 (s, br., 2H, NH2), 7.13–8.11 (m, 9H, ArH’s). Calcd.
or C24H18N6O2 (422.45): C, 68.24; H, 4.29; N, 19.98. Found: C,
8.10; H, 4.14; N, 20.00.
-Amino-3-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-
yrazol-4-yl)-3H-pyrido[2,1-b][1,3]benzothiazole-2,4-
icarbonitrile (23)
his compound was obtained as yellow crystals (EtOH), mp
20–21 ◦C, yield (79%); IR (cm−1): 3280, 3210 (NH2), 2216,
195 (CN), 1680 (CO), 1620 (C N), and 1595 (C C). 1H NMR
CD3)2SO: δ= 2.11 (s, 3H, CH3), 3.16 (s, 3H, CH3), 5.59 (s, 1H,
yran H-4), 6.15 (s, br., 2H, NH2), 7.13–7.91 (m, 9H, ArH’s). Calcd.
or C24H18N6OS (438.51): C, 65.74; H, 4.14; N, 19.16; S, 7.31.
ound: C, 65.82; H, 4.00; N, 19.25; S, 7.51.
-Amino-3-(1,5-dimethyl)-3-oxo-2-phenyl-2-3-dihydro-1H-
yrazol-4-yl-2,4-dimethylpyrido[1,2-a]quinazoline-6-one-2,4-
icarbonitrile
24)
his compound was obtained as yellow crystals (AcOH), mp
73–75 ◦C, yield (74%); IR (cm−1): 3335, 3280, 3210 (NH2), 2216,
195 (CN), 1680 (CO), 1620 (C N), and 1595 (C C). 1H NMR
CD3)2SO: δ= 2.11 (s, 3H, CH3), 3.16 (s, 3H, CH3), 5.25 (s, br., 2H,
H2), 7.13–8.27 (m, 9H, ArH’s). Calcd. for C25H17N7O2 (447.46):
, 67.11; H, 3.83; N, 21.91. Found: C, 67.20; H, 3.95; N, 22.00.
-(1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-
-yl)-1-oxo-1,5-dihydropyrido[1,2-a]benzimidazole-2,4-
icarbonitrile (25)
his compound was obtained as yellow crystals (DMF), mp
◦ −100–303 C, yield (82%); IR (cm ): 3280, 3210 (NH2), 2216,
195 (CN), 1680 (CO), 1620 (C N), and 1595 (C C). 1H NMR
CD3)2SO: δ= 2.11 (s, 3H, CH3), 3.16 (s, 3H, CH3), 7.13–8.37 (m,
0H, ArH’s and NH). Calcd. for C24H16N6O2 (420.43): C, 68.56;
, 3.84; N, 19.99. Found: C, 68.74; H, 3.72; N, 20.12.
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3-(1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)-1-
oxo-1H-pyrido[2,1-b][1,3]benzoxazole-2,4-dicarbonitrile (26)
This compound was obtained as yellow crystals (EtOH), mp
220–22 ◦C, yield (68%); IR (cm−1): 3280, 3210 (NH2), 2216,
2195 (CN), 1680 (CO), 1620 (C N), and 1595 (C C). 1H NMR
(CD3)2SO: δ= 2.11 (s, 3H, CH3), 3.16 (s, 3H, CH3), 7.13–8.12 (m,
9H, ArH’s). Calcd. for C24H15N5O3 (421.42): C, 68.40; H, 3.59; N,
16.62. Found: C, 68.25; H, 3.62; N, 16.80.
3-(1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)-1-
oxo-1H-pyrido[2,1-b][1,3]benzothiazole-2,4-dicarbonitrile (27)
This compound was obtained as yellow crystals (EtOH), mp
217–19 ◦C, yield (72%); IR (cm−1): 3280, 3210 (NH2), 2216,
2195 (CN), 1680 (CO), 1620 (C N), and 1595 (C C). 1H NMR
(CD3)2SO: δ= 2.11 (s, 3H, CH3), 3.16 (s, 3H, CH3), 7.13–8.92 (m,
9H, ArH’s). Calcd. for C24H15N5O2S (437.48): C, 65.89; H, 3.46;
N, 16.01, S, 7.33. Found: C, 65.90; H, 3.64; N, 15.90; S, 7.45.
7-(1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)-
9,11-dioxo-5,11-dihydro-9H-pyrido[2,1-b]quinazoline-6,8-
dicarbonitrile (29)
This compound was obtained as yellow crystals (EtOH), mp
236–37◦C, yield (67%); IR (cm−1): 3280, 3210 (NH2), 2216, 2195
(CN), 1700, 1680 (CO), 1620 (C N), and 1595 (C C). 1H NMR
(CD3)2SO: δ= 2.11 (s, 3H, CH3), 3.16 (s, 3H, CH3), 7.13–8.42 (m,
10H, ArH’s and pyridine H-3). Calcd. for C25H16N6O3 (448.44):
C, 66.96; H, 3.60; N, 18.74. Found: C, 66.82; H, 3.52; N,
18.92.
Results and discussion
Treatment of 1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-
pyrazole-4-carbaldehyde phenylhydrazone (2) with the appropriate
N-arylmaleimides in boiling anisole or bromobenzene gave 5-
aryl-tetrahydro-3-(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-
pyrazol-4-yl)-1-phenylpyrrolo[3,4-c]pyrazole-4,6(5H,6aH)-dione
3a–c and 5-aryl-1,6a-dihydro-3-(2,3-dihydro-1,5-dimethyl-3-
oxo-2-phenyl-1H-pyrazol-4-yl)-1-phenylpyrrolo[3,4-c]pyrazole-
4,6(3aH,5H)-dione 4a–c, respectively (Scheme 1). Structures 3 and
2
(
a
m
Scheme 1141
were elucidated by elemental analysis, spectral data, alternative
ynthetic route and chemical transformations. Thus, 1H NMR
pectrum of 3a showed signals at δ= 2.42 (s, 3H, CH3), 3.25 (s, 3H,
H3), 3.49 (t, 1H, J = 7.5 Hz, pyrazoline H-4), 4.64 (d, 1H, J = 7 Hz,
yrazoline H-5), 5.86 (t, 1H, pyrazoline H-3), 6.67–7.75 (m, 15H,
rH’s), 10.05 (s, br., 1H, NH). 1H NMR spectrum of 4a showed
ignals at δ= 2.61 (s, 3H, CH3), 3.24 (s, 3H, CH3), 4.88 (d, 1H,
= 9 Hz, pyrazoline H-4), 5.85 (d, 1H, J = 9 Hz, pyrazoline H-5),
.98–7.58 (m, 15H, ArH’s). Reactions took place via 1,3-addition
f hydrazone to double bond maleimides, followed by cyclisation
o give 3. This oxidised readily to give 4. Further, treatment of
,5-dimethyl-3-oxo-N,2-diphenyl-2,3-dihydro-1H-pyrazole-4-
arbohydrazonoyl bromide (6), which was synthesised via reaction
f 2 with N-bromosuccinimide in toluene with the appropriate
-arylmaleimides in boiling toluene containing triethylamine,
fforded products identical in all aspects (mp, mixed mp, and
pectra) with 4a–c.
Oxidation of 4c with p-chloroanil in boiling xylene gave 5-(4-
hlorophenyl)-3-(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-
yrazol-4-yl)-1-phenylpyrrolo[3,4-c]pyrazole-4,6(1H,5H)-dione
5c). 1H NMR spectrum of 5c showed signals at δ= 2.42 (s, 3H,
H3), 3.25 (s, 3H, CH3), 7.18–7.78 (m, 14H, ArH’s) (Scheme 1).
Treatment of 2,5-dihydro-2,3-dimethyl-5-oxo-1-phenyl-1H-
yrazole-4-carbaldehyde (1) with each of malononitrile,
thyl cyanoacetate, 1H-benzimidazol-2-ylacetonitrile, 1,3-ben-
oxazol-2-ylacetonitrile, 1,3-benothiazole-2-ylacetonitrile, (4-oxo-
,4-dihydroquinazolin-2-yl)acetonitrile or 3-oxo-3-phenylpropane-
itrile in ethanol gave 2-((2,5-dihydro-2,3-dimethyl-5-oxo-
-phenyl-1H-pyrazol-4-yl)methylene)malononitrile (7), ethyl 2-
yano-3-(2,5-dihydro-2,3-dimethyl-5-oxo-1-phenyl-1H-pyrazol-
-yl)acrylate (8), 2-(1H-benzimidazol-2-yl)-3-(1,5-dimethyl-3-
xo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)acrylonitrile (9), 2-
1,3-benzoxazol-2-yl)-3-(1,5-dimethyl-3-oxo-2-phenyl-2,3-
ihydro-1H-pyrazol-4-yl)acrylonitrile (10), 2-(1,3-benzothiazol-
-yl)-3-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-
l)-acrylonitrile (11), 3-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihy-
ro-1H-pyrazol-4-yl)-2-(4-oxo-3,4-dihydroquinazolin-2-yl)acryl-
nitrile (12) and 2-benzoyl-3-(1,5-dimethyl-3-oxo-2-phenyl-
,3-dihydro-1H-pyrazol-4-yl)acrylonitrile (13), respectively
Scheme 2). The structures 8–13 were confirmed by elemental
nalyses, spectral data and chemical transformations.
Treatment of 7 with 3-methyl-1H-pyrazol-5(4H)-one or 3-
ethyl-1-phenyl-1H-pyrazol-5(4H)-one in ethanol containing a
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atalytic amount of piperidine afforded 6-amino-1,4-dihydro-4-
2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)-3-
ethylpyrano[2,3-c]pyrazole-5-carbonitrile (14) and 6-amino-1,4-
ihydro-4-(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-
-yl)-3-methyl-1-phenyl-pyrano[2,3-c]pyrazole-5-carbonitrile
15) (Scheme 3). This reaction occurred via the addition of
,4-Micheal to form the intermediate, which readily cyclised to
ive the pyran derivatives as final product 14, 15. The structures
4 and 15 were elucidated by elemental analysis, spectra and
lternative synthetic routes. Malononitrile was reacted with
-[(2,3-dimethyl-5-oxo-1-phenyl(3-pyrazolin-4-yl))methylene]-
-methyl-2-phenyl-1-pyrazolin-4-one (16), synthesised via
eaction of 1 with 3-methyl-1-phenyl-1H-pyrazol-5(4H)-one
n presence of a catalytic amount of piperidine to afford a
roduct identical in all aspects (mp, mixed mp and spectra)
ith 15.
Analogously, compound 7 reacted with the appropriate
f 2-thioxoimidazolidin-4-one, 1-phenyl-2-thioxoimidazolidin-
a
p
z
3
Scheme 3-one, 3-phenyl-2-thioxoimidazolidin-4-one or 1,3-diphenyl-2-
hioxoimidazolidin-4-one to give 2-thioxo-4H-pyrano[2,3-d]4-
midazolines 17–20, respectively (Scheme 3).
Also, treatment of 7 with (1H-benzimidazol-2-yl)acetonitrile
n ethanol containing a catalytic amount of piperidine gave
-amino-3-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-
yrazol-4-yl)pyrido[1,2-a]benzimidazole-2,4-dicarbonitrile
21) (Scheme 4). Structure 21 was confirmed by elemental
nalysis, spectral data and alternative synthesis. Thus, treatment
f 2-(1H-benzimidazol-2-yl)-3-(1,5-dimethyl-3-oxo-2-phenyl-
,3-dihydro-1H-pyrazol-4-yl)acrylonitrile (9), gave an identical
roduct (mp, mixed mp, and spectra) with 21.
Treatment of 1,3-benzoxazol-2-ylacetonitrile or 1,3-benzo-
hiazol-2-ylacetonitrile with 7 in ethanol containing a catalytic
mount of piperidine gave 1-amino-3-(1,5-dimethyl-3-oxo-2-
henyl-2,3-dihydro-1H-pyrazol-4-yl)-3H-pyrido[2,1-b][1,3]ben-
oxazole-2,4-dicarbonitrile (22) and 1-amino-3-(1,5-dimethyl-
-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)-3H-pyrido[2,1-b]
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[1,3]benzothiazole-2,4-dicarbonitrile (23), respectively. The
structures 22 and 23 were elucidated by elemental analysis,
spectral data and alternative synthetic routes. Thus, ethyl cyanoac-
etate reacted with each of 10 or 11 to afford products identical
in all aspects (mp, mixed mp and spectra) with 22 and 23,
respectively.
Similarly, compound 7 reacted with (4-oxo-1,4-
dihydroquinazolin-2-yl)acetonitrile in ethanolic piperidine
solution to give 1-amino-3-(1,5-dimethyl-3-oxo-2-phenyl-2,3-
dihydro-1H-pyrazol-4-yl)-2,4-dimethylpyrido[1,2-a]quinazoline-
6-one-2,4-dicarbonitrile (24). Furthermore, 24 was also synthesised
via reaction of 3-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-
pyrazol-4-yl)-2-(4-oxo-3,4-dihydro-quinazolin-2-yl)-acrylonitrile
(12) reacted with malononitrile in ethanolic piperidine solution.
On the other hand, treatment of ethyl 2-cyano-3-(1,5-
dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)acrylate
(8) with the appropriate (1H-benzimidazol-2-yl)acetonitile,
1,3-benoxazol-2-ylacetonitrile, 1,3-benzothiazol-2-ylacetonitrile
or (4-oxo-1,4-dihydroquinazolin-2-yl)acetonitrile gave 3-(1,5-
dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)-1-oxo-
1,5-dihydropyrido-[1,2-a]benzimidazole-2,4-dicarbonitrile (25),
a
r
m
t
Scheme 5-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)-1-
xo-1H-pyrido[2,1-b][1,3]-benzoxazole-2,4-dicarbonitrile (26),
-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)-4
1-oxo-1H-pyrido[2,1-b][1,3]benzothiazole-2,4-dicarbonitrile (27)
nd 7-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-
l)-9,11-dioxo-5,11-dihydro-9H-pyrido[2,1-b]quinazoline-6,8-
icarbonitrile (29), respectively (Scheme 5). Structures of 25–27
nd 29 were elucidated by elemental analyses, spectra and alter-
ative synthetic route. Thus, ethyl cyanoacetate was reacted with
he appropriate 9–12 in ethanol containing a catalytic amount of
iperidine to give identical products in all aspects (mp, mixed mp
nd spectra) with 25–27 and 29, respectively.
In contrast, treatment of 2-benzoyl-3-(1,5-dimethyl-3-oxo-
-phenyl-2,3-dihydro-1H-pyrazol-4-yl)acrylonitrile (13) with the
ppropriate (1H-benzimidazol-2-yl)acetonitrile, 1,3-benzoxazol-
-ylacetonitrile, 1,3-benzothiazol-2-ylacetonitrile or (4-oxo-1,4-
ihydroquinazolin-2-yl)acetonitrile in ethanol containing a catalytic
mount of piperidine gave 9–12, respectively (Scheme 6). The
eaction occurred via the addition of 1,4-Micheal to form the inter-
ediate 30 which readily loses one molecule of benzoylacetonitrile
o give the final products 9–11.
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